SpeeDx Receives CE-IVD Clearance for ResistancePlus MG FleXible
6.9.2019 09:00:00 EEST | Business Wire | Press release
SpeeDx Pty, Ltd. today announced Resistance Plus® MG FleXible for the Cepheid GeneXpert® System, detecting the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers associated with azithromycin resistance, received CE-IVD mark for sale in Europe. This is the first test to be launched under Cepheid’s FleXible Cartridge programme, partnering with SpeeDx – a trusted assay manufacturer – to provide access to the GeneXpert sample-to-answer FleXible cartridge.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905006074/en/
ResistancePlus MG FleXible simultaneously detects M. genitalium (Mgen) and macrolide resistance. SpeeDx, a trusted assay manufacturer, has partnered with Cepheid to provide Resistance Guided Therapy for Mgen on the GeneXpert sample-to-answer FleXible cartridge. (Photo: Business Wire)
“ResistancePlus MG FleXible represents both an evolution of our technology and of Resistance Guided Therapy for Mgen”, said Colin Denver SpeeDx CEO. “There is considerable interest by clinicians and laboratories alike, as it will now be even easier to adhere to international and local management guidelines and provide clinically relevant and timely information to manage the growing problem of macrolide resistance in Mgen infections.”
Mgen can cause symptoms such as urethritis, cervicitis, endometritis and pelvic inflammatory disease, and has been linked to reproductive health complications including pre-term birth and infertility.1,2 Macrolide antibiotics, specifically azithromycin, are the first-line treatment for the rapidly growing problem of Mgen, but resistance to these antibiotics has increased up to 50% in several countries.4-6 There are limited alternative treatment options, many of which are expensive, difficult to access, or associated with undesirable side-effects.4,5 Current Mgen guidelines focus on extending the utility of azithromycin by testing for macrolide resistance-associated mutations and stratifying patient treatment accordingly.1-3
“SpeeDx offers unique technology for simultaneous detection of pathogens and drug resistance directly from clinical specimens. Together, we have leveraged the open architecture of our new FleXible cartridge to enable detection of this emerging drug-resistant pathogen on the GeneXpert System,” said David H. Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer. “The ResistancePlus MG Flexible cartridge offers best-in-class performance in an easy to use, on-demand format to address a significant medical need in symptomatic individuals, and adds to the growing portfolio of STI testing options available on our platform.”
Timely detection of antibiotic resistant infections enables Resistance Guided Therapy, resulting in better treatment of the disease for patients, reduced potential for spreading infection among vulnerable populations, and supporting antibiotic stewardship to combat rising antibiotic resistance.
Resistance Plus® MG FleXible will be exclusively distributed by Cepheid.
About SpeeDx
SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. The SpeeDx Resistance Plus® MG open-platform assay is CE marked for sale in Europe, TGA approved for sale in Australia and clinical trials are being finalised for submission to the U.S. FDA. Products in the SpeeDx portfolio focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
For more information on SpeeDx please see: https://plexpcr.com
- Jensen JS, Cusini M, Gomberg M, Moi H. 2016. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. PMID: 27505296.
- https://www.bashhguidelines.org/media/1146/ngu-update-05_2017-final.pdf
- http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium
- Read T R H, Fairley C K, Murray G L, et al. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation, Clinical Infectious Diseases, ciy477, https://doi.org/10.1093/cid/ciy477
- Getman D, Jiang A, O'Donnell M, Cohen S. 2016. Mycoplasma genitalium prevalence, coinfection, and macrolide antibiotic resistance frequency in a multicenter clinical study cohort in the United States. J Clin Microbiol 54:2278-2283.
- Murray GL, Bradshaw CS, Bissessor M, et al. Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium. Emerging Infectious Diseases. 2017;23(5):809-812. doi:10.3201/eid2305.161745.
- Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004; 291:2229–2236.
- Unemo, M. & Jensen, J.S. ‘Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium’. 2016. Nat. Rev. Urol.268. Published online 10 Jan 2017. doi:10.1038/nrurol
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905006074/en/
Contact information
SpeeDx:
Europe, Australia, New Zealand:
Madeline O’Donoghue
+61 2 9209 4170
madelineo@speedx.com.au
USA:
Rick Roose
+1 415.202.4445
roi.roose@gmail.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Chambers Organises Open Dialogue in London to Showcase Dubai’s Competitive Advantages as a Global Business Hub16.6.2026 12:25:00 EEST | Press release
Dubai Chambers organised an open dialogue in London in cooperation with the London Chamber of Commerce and Industry (LCCI) aimed at showcasing Dubai’s competitive advantages as a global business hub to a group of leading British investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616827193/en/ H.E. Mohammad Ali Rashed Lootah addresses the audience during the event (Photo: AETOSWire) The event was attended by His Excellency Mohammad Ali Rashed Lootah, President and CEO of Dubai Chambers, together with UK business leaders. Discussions highlighted the key investment opportunities Dubai offers across diverse sectors, as well as the city’s advantages as a hub for the expansion of British companies in the region and globally. The session also outlined the comprehensive support provided by Dubai Chambers to UK investors to ensure the smooth establishment and growth of their businesses in Dubai. The discussions explored how
NIQ and Unlimitail Collaborate to Deliver the Next Generation of Omnichannel Retail Media Insights & Measurement Across Retailers and Countries16.6.2026 12:00:00 EEST | Press release
Retail media investment is accelerating globally, with 67% of CMOs planning to increase spending on retail media networks (RMNs) in 2026. Yet only 53% believe today's RMNs provide adequate measurement and attribution capabilities, highlighting a critical gap in proving true business impact across retailers and markets.* Today, NIQ (NYSE: NIQ), a leading consumer intelligence company, and Unlimitail, a leading retail media network, announced a strategic collaboration designed to help brands and retailers unlock a new era of retail media accountability through advanced measurement, consumer insights, interoperable data infrastructure, and AI-powered analytics. This collaboration will combine Unlimitail's extensive retail media network, which spans 21 countries, 35 retailers, more than 120 retailer websites, and over 250 million loyalty cardholders, with NIQ's industry-leading measurement, analytics, and consumer intelligence capabilities. Together, the companies will help advertisers mov
Thredd Expands Partnership with ID DISTRIBUTION to Power Next Phase of Employee Benefits and Expense Innovation16.6.2026 12:00:00 EEST | Press release
Thredd, the AI-first issuer processing platform, today announced an expanded partnership with ID DISTRIBUTIONthrough its flagship program Vaziva, a leading employee benefits and payments platform, to support its growth beyond consumer payments, into corporate payments, as well as their international expansion. Thredd has worked with ID DISTRIBUTIONsince 2020, supporting the company’s consumer offering in France with physical and digital card issuing and payments processing capabilities. Its Vaziva card program enables companies to digitally manage and distribute multiple types of employee benefits through a single prepaid Mastercard-branded card experience. The program supports convenient, secure card usage for employees to access and use benefits across categories including lunch, gifts, culture, holidays, and travel. With more employers seeking simpler, more digital ways to manage employee benefits and purchasing, IDD is building on its existing consumer card programme to launch a ne
Respond.io Raises $62.5M Series B to Scale AI-Powered Customer Conversations Into North America and Europe16.6.2026 11:00:00 EEST | Press release
Respond.io, a customer conversation management platform, today announced a $62.5 million Series B round led by Camber Partners, with participation from Endeavor Catalyst and existing investors. What respond.io does Respond.io enables mid-market B2C businesses to grow revenue from high volumes of customer chats and calls. It unifies WhatsApp, Instagram, TikTok, Messenger, LINE, Telegram, WeChat, voice calls, email, web chat and 16 more integrations into a single platform with AI agents, automation, and CRMs. This turns fragmented customer conversations into a measurable revenue engine, purpose-built for real-world scale and complexity. The company serves industries where customers initiate conversations before buying, booking, or committing, including education, healthcare, automotive, retail and travel. The platform powers 2 billion messages per quarter for more than 10,000 businesses in over 180 countries, including Toyota, British Airways, Radisson, Hertz, and Decathlon. Respond.io g
Eastnets Launches FinCrime Intelligence Platform to Unify Financial Crime Investigations16.6.2026 11:00:00 EEST | Press release
Eastnets, a global provider of compliance and payment solutions, today announced the launch of FinCrime Intelligence Platform (FCIP), a new investigation and orchestration layer that helps financial institutions unify financial crime operations, improve investigator productivity and gain a single view of risk across AML, sanctions, KYC and fraud. As financial crime operations grow in complexity, many institutions struggle with fragmented investigation tools and inconsistent workflows. FCIP addresses this challenge by providing a single, governed workspace for managing cases across compliance domains - without replacing existing detection systems. Eastnets’ FinCrime Intelligence Platform delivers centralised case management across AML, sanctions screening and KYC, structured, multi‑level investigative workflows with assistive, explainable AI to support, and not replace, human decision-making, providing full audit trails and management oversight. By consolidating AML, fraud, KYC, and scr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom